HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.

AbstractBACKGROUND:
The noninvasive evaluation of nigrostriatal dopaminergic integrity by PET can provide useful information for the differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD).
OBJECTIVES:
To evaluate the diagnostic potential of imaging striatal monoaminergic terminal integrity with the novel vesicular monoamine transporter type 2 (VMAT2) radioligand [(18)F]AV-133 and PET to distinguish DLB from AD.
METHODS:
Fifty participants [9 DLB, 11 AD, 20 Parkinson's disease (PD) and 10 healthy age-matched control subjects (HC)] underwent [(18)F]AV-133 PET studies. Additionally, 20 participants underwent amyloid imaging PET scans with either [(11)C]PiB or (18)F-florbetaben. VMAT2 density was calculated through normalized tissue uptake value ratios (R(T)) at 120-140 min after injection using the primary visual or the cerebellar cortex as reference region. Comparison of the R(T) for [(18)F]AV-133 was done between the different clinical diagnostic groups.
RESULTS:
Significantly lower striatal VMAT2 densities were observed in DLB and PD when compared to AD and HC, especially in the posterior putamen. In contrast to PD and DLB, no reductions were observed in AD patients when compared to HC.
CONCLUSIONS:
[(18)F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. In contrast to amyloid imaging, VMAT2 imaging with [(18)F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in DLB patients, assisting in the differential diagnosis from AD.
AuthorsVictor L Villemagne, Nobuyuki Okamura, Svetlana Pejoska, John Drago, Rachel S Mulligan, Gaël Chételat, Graeme O'Keefe, Gareth Jones, Hank F Kung, Michael Pontecorvo, Colin L Masters, Daniel M Skovronsky, Christopher C Rowe
JournalNeuro-degenerative diseases (Neurodegener Dis) Vol. 10 Issue 1-4 Pg. 161-5 ( 2012) ISSN: 1660-2862 [Electronic] Switzerland
PMID22261520 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 S. Karger AG, Basel.
Chemical References
  • 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
  • Aniline Compounds
  • Carbon Radioisotopes
  • Fluorine Radioisotopes
  • SLC18A2 protein, human
  • Thiazoles
  • Vesicular Monoamine Transport Proteins
  • florbenazine F 18
  • Tetrabenazine
Topics
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease (diagnostic imaging)
  • Amygdala (diagnostic imaging, pathology)
  • Aniline Compounds
  • Brain Mapping
  • Carbon Radioisotopes
  • Case-Control Studies
  • Corpus Striatum (diagnostic imaging, pathology)
  • Diagnosis, Differential
  • Female
  • Fluorine Radioisotopes
  • Humans
  • Lewy Body Disease (diagnostic imaging)
  • Male
  • Middle Aged
  • Positron-Emission Tomography (methods)
  • Tetrabenazine (analogs & derivatives)
  • Thiazoles
  • Vesicular Monoamine Transport Proteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: